Article
A randomized, prospective dosage-finding study of intravitreal Triamcinolone Acetonide on diabetic maculopathy and exudative AMD
Search Medline for
Authors
Published: | September 22, 2004 |
---|
Outline
Text
Objective
To evaluate efficacy of different dosages of intravitreal triamcinolone acetonide on diabetic maculopathy and exsudative age related maculopathy (ARMD).
Methods
The prospective, randomized, double masced study included 60 eyes of 60 patients with diabetic maculopathy (n=32 eyes) or exsudative age related macular maculopathy (AMD) (n=28). A randomized dosage of 4mg, 8mg or 25mg crystalline triamcinolone acetonide was injected. Main outcome measure was the visual acuity (ETDRS) after 1, 3 and 6 months.
Results
Without regard to dosage, visual acuity gain was higher in patients with diabetic maculopathy than ARMD. Treatment response was immediate and significantly (p<0.05) earlier in patients with diabetic maculopathy (1 week follow-up, all dosages) than in patients with AMD (1 month follow-up, all dosages). After 3 months follow-up, patients with diabetic maculopathy had a significant higher increase in VA after injection of 25mg than after injection of 8mg and 4mg. After 6 months all dosages demonstrated a VA loss (4mg and 8mg > 25mg). Patients with ARMD showed no significant increase in VA with all dosages.
Conclusions
An intravitreal triamcinolone acetonide injection results in a higher VA increase in eyes with diabetic maculopathy than in eyes with ARMD. After a follow-up of 6 months, the treatment response occurs faster and longer lasting after an injection of 25mg than 8mg or 4mg.